These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
531 related articles for article (PubMed ID: 18366448)
1. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448 [TBL] [Abstract][Full Text] [Related]
2. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924 [TBL] [Abstract][Full Text] [Related]
4. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709 [TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104 [TBL] [Abstract][Full Text] [Related]
6. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920 [TBL] [Abstract][Full Text] [Related]
7. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960 [TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. McRae M; Clay PG; Anderson PL; Glaros AG Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947 [TBL] [Abstract][Full Text] [Related]
12. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951 [TBL] [Abstract][Full Text] [Related]
13. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. Noor MA; Flint OP; Maa JF; Parker RA AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722 [TBL] [Abstract][Full Text] [Related]
14. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064 [TBL] [Abstract][Full Text] [Related]
15. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877 [TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. Isaac A; Taylor S; Cane P; Smit E; Gibbons SE; White DJ; Drake SM; Khoo S; Back DJ J Antimicrob Chemother; 2004 Aug; 54(2):498-502. PubMed ID: 15254024 [TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine. Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190 [TBL] [Abstract][Full Text] [Related]